Aeterna Zentaris (AEZS) Reports Zoptrex Presentation in Prostate Cancer at GenitourinaryCancers Symposium
Tweet Send to a Friend
Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced that a poster entitled, “A phase II trial of zoptarelin doxorubicin in castration-and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
